Re: A prospective analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized phase III clinical trial using limited hormonal therapy.
Pickles
Tom
T
D000728:Androgens / Q000097:blood; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood; D017326:Clinical Trials, Phase III as Topic; D007987:Gonadotropin-Releasing Hormone / Q000627:therapeutic use; D017273:Goserelin / Q000627:therapeutic use; D006801:Humans; D016729:Leuprolide / Q000627:therapeutic use; D008297:Male; D011471:Prostatic Neoplasms / Q000097:blood* / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D013739:Testosterone / Q000037:antagonists & inhibitors* / Q000097:blood*
D000728:Androgens; D018931:Antineoplastic Agents, Hormonal; D014408:Biomarkers, Tumor; D017273:Goserelin; D007987:Gonadotropin-Releasing Hormone; D013739:Testosterone; D016729:Leuprolide